US FDA approves Regeneron's rare bone disorder drug
REGN•FDA approves experimental treatment
Aug. 19 - The U.S. Food and Drug Administration on Wednesday approved Regeneron's REGN.O experimental treatment for a rare genetic disorder after the drug significantly reduced abnormal bone formation in certain soft tissues.
